^
Association details:
Biomarker:BRAF D594G
Cancer:Melanoma
Drug:ulixertinib (BVD-523) (ERK2 inhibitor, ERK1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Updated clinical outcomes from ULI-EAP-100, an intermediate expanded access program for ulixertinib (BVD-523).

Published date:
05/26/2022
Excerpt:
ULI-EAP-100 (NCT04566393) is an ongoing intermediate expanded access protocol (EAP) that offers ulixertinib to US patients with advanced solid tumors harboring MAPK pathway alterations..A BRAF D594G melanoma pt’s tumor rapidly shrunk with monotherapy permitting surgery and rendering pt with no evidence of disease...
DOI:
10.1200/JCO.2022.40.16_suppl.e15101
Trial ID: